# About Wolverine Order: An Independent BPC-157 TB-500 Reading-Room

> About Wolverine Order — an independent editorial project publishing plain-language summaries of the peer-reviewed BPC-157 TB-500 research record. Not a clinic, not a vendor, not a prescriber.

We summarize the published research on BPC-157 and TB-500 — gently, plainly, and with every gap labelled. We are not a clinic and we sell nothing.

## What Wolverine Order is

Wolverine Order is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 "Wolverine" blend and its two constituents. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site exists because this particular blend is unusually easy to misread. Two real peptides, each with a genuine research literature, get bundled into a single product whose combined effect has never actually been tested. Forum copy and supplier pages tend to smooth over that gap. Our whole editorial discipline is to keep it visible — to label which leg of the blend a finding belongs to, to mark animal-model results as animal-model results, and to say "no blend-level trial" wherever that is the truth.

## About the name, and about access

The word "Order" in our name is editorial framing, not a service we provide. It refers to the order of access — how compounded access to substances like these is governed, evaluated, and sequenced — and to the work of putting a messy literature into some order. It is a position this publisher occupies relative to the record, not a claim that the site takes orders, fills prescriptions, or offers treatment, consultation, or any product. We do none of those things.

That distinction is why our regulatory page reads the way it does. We describe how lawful compounded access is structured in general terms, and we state the present-tense FDA status of each peptide, sourced to the FDA. We name no pharmacy, clinic, or provider, we give no dosing, and we describe no way to obtain a restricted substance outside the lawful framework. The aim is plain information about the landscape — not advice, and not a transaction.

## How we work

Every quantitative claim on this site maps to a numbered citation in our reference list, and those citations point to primary sources: PubMed-indexed studies, peer-reviewed reviews, and official FDA pages. When the evidence is strong, we say so plainly. When it is thin, preclinical, or absent — as it is for the combination itself — we say that just as plainly. Honesty about the gaps is the point of the project, and a soft, readable presentation is how we try to make that honesty easy to take in rather than easy to skip.

---

A soft pastel reading-room for the BPC-157 and TB-500 record — each peptide read kindly against its own studies, the missing blend trial left plainly unfilled, and the FDA 503A status set out gently; nothing is dispensed and nothing is sold here.